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Abstract 
Objective: To evaluate the clinical and morphological features in advanced phase chronic myeloid leukaemia. 
Methods: This descriptive observational study was conducted at the Pathology Unit of Fauji Foundation Hospital, 
Rawalpindi from June 2012 till June 2016. Diagnosed patients of chronic myeloid leukaemia in the accelerated and 
blast phase of the disease were included in the study. History was taken, physical examination, complete blood 
counts, peripheral blood film examination, and bone marrow biopsy was done. 
Results: The mean age in the advanced phase was 47 years. The female to male ratio was 5:1. 19 patients were in 
blast phase; 14( 74%) in myeloid transformation, 4(21%) patients in lymphoblastic transformation and 1(05%) 
patient transformed into acute biphenotypic leukaemia showing both lymphoid and myeloid markers. Forty-six 
patients were in the accelerated phase. 
Conclusion: There is usually not a single criterion for the transition into accelerated phase but certain variables 
coexist at the same time. 
Keywords: Chronic myeloid leukaemia, advanced phase, blast phase, WHO classification. 
 
 
Introduction 
 
Chronic myeloid leukaemia (CML) is a 
myeloproliferative disorder. The underlying pathology 
is a transcript formed by the fusion of the BCR- ABL1 
gene that is present in the Philadelphia chromosome.1 
The Philadelphia chromosome is formed by the 
reciprocal translocation between chromosomes 9 and 
22. This balanced chromosomal translocation causes 
the fusion of the Abelson oncogene (ABL) from 
chromosome 9q34 with the breakpoint cluster region 
(BCR) on chromosome 22q11.2, t(9;22)(q34;q11.2) and 
results in the formation of BCR-ABL1 fusion gene, this 
gene then translates into Bcr-Abl oncoprotein which 
has a molecular weight of 210 kD. It has an increased 
tyrosine kinase activity which not only results in 
leukemic cell growth but it also contributes to the 
clonal evolution of the disease.1 
The fusion of transcript BCR-ABL translates into a Bcr-
Abl oncoprotein. This oncoprotein most frequently has 
a molecular weight of 210 kD (p. 210) and displays 
increased tyrosine kinase activity which causes growth 
factor independence and leukemic cell growth in 
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hematopoietic cell lines, contributes also to the clonal 
evolution of the disease and leads to its evolution 
toward acute leukemia,  results in an increase in the 
activity of the enzyme tyrosine kinase which leads to 
increase proliferation of myeloid cells.2 The course of 
CML is either biphasic or triphasic. In patients who are 
untreated, it includes an initial chronic phase, an 
accelerated phase, and a blast phase.3 The 
management of patients in the advance phase becomes 
challenging as compared to chronic phase especially if 
there is a new cytogenetic clonal evolution or there is a 
development of some resistant mutation.5 
 
WHO criteria for accelerated phase (AP): 4 
 
1. Persistent or increasing WBC count of more than 
10,000/μL and/or persistent or increasing 
splenomegaly unresponsive to therapy. 
2. Persistent thrombocytosis with a platelet count of 
more than 1,000 × 103/μl, uncontrolled by therapy. 
3. Persistent thrombocytopenia with a platelet count 
of less than 100 × 103/μl, unrelated to therapy. 
4. Evidence of cytogenetic evolution occurring after 
the initial diagnostic karyotype 
5. 20% or more basophils in the peripheral blood. 
6. 10% to 19% myeloblasts in the blood or bone 
marrow. 
 
WHO criteria for blast phase (BP): 4 
 
1. Blasts equal to or greater than 20% of the 
peripheral blood leukocytes or of the 
nucleated cells of the bone marrow.  
2. An extramedullary proliferation of blasts.  
 
The data reported in patients showed a majority of 
patients (96.8%) in the chronic phase while few 
patients were in accelerated and blast phases (2.2% ) 
and (0.9%) respectively. Imatinib is a drug that 
selectively inhibits tyrosine kinase activity and it is the 
drug of choice in patients with chronic myeloid 
leukaemia.6 It has been observed that life expectancy 
of patients in the chronic phase of the disease can be 
comparable to general healthy population however 
accelerated and blast phase of the disease still 
represents a challenge especially after failing to 
respond to tyrosine kinase inhibitors.6 
 
Material and Methods 
 
This descriptive study was conducted at the Pathology 
Unit of Fauji Foundation Hospital, Rawalpindi from 
June 2012 till June 2016. Only those patients who were 
in the advance phase of the disease (AP and BP) were 
included in this study. Patients who were in the 
chronic phase were excluded.  
A thorough history was taken and a detailed physical 
examination was done in all patients. A complete 
blood picture was performed on automated 
hematology analyzer Sysmex 1800i. Peripheral blood 
film was stained with Leishman stain and bone 
marrow aspiration was done using Salah bone marrow 
aspiration needle and trephine biopsy using a trephine 
biopsy needle and stained with Leishman stain. 
Cytochemistry for bone marrow aspiration slides was 
done using Sudan Black B, chloroacetate esterase, acid 
phosphatase, and alpha naphthyl acetate esterase 
stains. Hematoxylin & eosin staining was done on 
trephine biopsy slides and were needed for Gomori 
reticulin stain for presence and grading of fibrosis. 
Reporting of the peripheral film was done by a fourth-
year hematology resident and bone marrow aspiration 
and trephine biopsy reporting were done by 
consultant hematologist/histopathologist. The 
Immunophenotype of selected cases was sent to the 
Armed Forces Institute of Pathology, Rawalpindi. 
WHO 2008 criteria were used to categorize the 
patients in AP and BP. Informed written consent was 
taken from the patient and permission was sought 
from the hospital ethical committee. The data were 
analyzed through SPSS for windows version 11. The 
numerical data i.e. age is reported as mean ± S.D. The 
categorical data i.e. gender and different phases of the 
disease were expressed as frequencies (percentages). 
 
Result 
 
The mean age of patients in the advanced phase was 
47 years. The female to male ratio was 5:1. A total of 65 
patients were in advance phase out of which 19 
patients were in the blast phase while 46 patients were 
in the accelerated phase as shown in Figure-I. 
In Table I Marrow fibrosis in the accelerated phase 
was seen in 15 patients of chronic myeloid leukaemia. 
The fibrosis was between grades 1-3 according to 
WHO defined 4-point scoring system.4 
The diagnosis of AML and ALL were based on bone 
marrow aspirate examination followed by 
cytochemistry with myeloperoxidase stain, Sudan 
black- B stain, alpha naphthyl acetate esterase, 
chloroacetate esterase, and periodic acid Schiff stain. 
The patient with biphenotypic leukaemia had a 
hypercellular marrow comprising of more than 90% 
heterogeneous blast cells. On immunophenotyping 
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theses, blasts showed dual expression of CD33 and CD 
19, CD34, iCD22, TdT, and MPO.  
 
 
 
FIGURE-I: A total of 65 patients were in the advance 
phase. 19 patients in the accelerated phase and 46 
patients were in the blast phase. 
 
Table-I showing clinical and laboratory features in 
the accelerated phase of chronic myeloid leukaemia. 
                          CLINICAL 
FEATURES 
FREQUENCY (%) 
Blast between 10-19% 10(21%) 
Increased Blasts + 
thrombocytosis 
04(08%) 
Increased Blasts + Increasing 
Splenomegaly 
04(08%) 
Increased Blasts + Increasing 
WBCs 
05(10%) 
Increased Blasts 
+Thrombocytosis + Increased 
Basophils 
03(06%) 
Thrombocytopenia +Increasing 
Splenomegaly 
02(04%) 
Thrombocytosis +Increasing 
WBCS 
02(04%) 
Thrombocytosis + increasing 
splenomegaly 
04 (08%) 
Increased Basophils only 02(06%) 
Thrombocytosis only 03(06%) 
Increased Basophils+ Increased 
Blasts +Increasing 
splenomegaly+Thrombocytosis 
04(08%) 
Increasing 
Splenomegaly+Increased WBC 
03(06%) 
 
Figure-II: Distribution of blast phase of the disease: 14 
patients transformed into acute myeloid leukaemia, 4 
patients into acute lymphoblastic leukaemia and 1 
patient into biphenotypic leukaemia. 
 
Figure-III: Chronic Myeloid Leukaemia in Accelerated  
Phase showing an increased number of blast cells. 
 
Discussion 
 
The annual incidence of CML is 1.6 per 100,000 
population. The median age of onset of chronic 
myeloid leukaemia is 53 years.7 The mean age of onset 
of CML in our study was 47 years. In a local study, the 
mean age was found to be 37 years, the younger age 
group was due to the inclusion of patients in both the 
chronic and advanced phases while our study 
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included patients in advanced phase only.8 The reason 
being chronic myeloid leukaemia presents at a 
younger age in this part of the world compared to 
Western countries.9,10 The local series results are 
consistent with a younger age where the mean age of 
presentation of this disease was found to be 34-37 
years.11  
CML in its advanced stage comprises an accelerated 
phase (AP) which is followed by a more aggressive 
phase which is the blast phase (BP). However, it has 
been observed that some of the patients do not go 
through the accelerated stage of this disease and they 
directly progress to the blast phase. 12,13Our study 
showed a total of 65 patients were in advance phase 
out of which 46 (70%) patients were in accelerated 
phase, 19 (30%) patients were found to be in a more 
aggressive blast phase. In a study done locally, 35 
(77.8%) patients were found to be in chronic phase, 
while 7 (15.5%) patients were in accelerated phase and 
3 (6.7%) patients were in the blast phase of the disease 
.8 In a local study that included 275 patients of CML, 
the percentage of patients in different stages of the 
disease were CP (87.3%), AP (8.1%) and BP (4.7%).14  
In a study done on CML in France the frequency of 
CP, AP and BP were found to be 96.8%, 2.2%, and 
0.9% respectively.9 In comparison to having included 
patients in all three phases of the disease our data, 
there is a difference in the number of patients in 
various phases of the disease the reason for the 
difference in statistics is these studies and not just the 
advance phase. The accelerated phase of CML is 
characterized either by the deterioration of the 
hematologic parameters or there could be worsening 
of the physical condition of the patient. There is not a 
single criterion but a number of criteria to define CML-
AP.15,16,17 In our study patients who were in the 
accelerated phase of the disease did not have a single 
criterion but had multiple features of accelerated 
phase.16 
According to WHO in blast phase of chronic myeloid 
leukaemia 70% transform into acute myeloid 
leukaemia, 20% transform into acute lymphoblastic 
leukaemia, the rest transform into 
biphenotypic/bilineage leukaemia.4 
In, an international study was done, the majority of 
patients in the blast phase transformed into acute 
myeloid leukaemia. 25% of the patients transformed 
into acute lymphoblastic leukaemia (pre-B).18 Rarely 
transformation into acute lymphoblastic leukaemia (T-
type) has also been identified.19,20  
In another study, about 70% of patients in acute 
transformation had blasts classifiable as myeloid 
leukaemia with myeloblastic or myelomonocytic type 
predominance.21 CML may transform into acute 
lymphoblastic leukaemia in approximately 30 % of 
patients. The lymphoid cells generally express 
terminal deoxynucleotide transferase (TDT). The 
above study conforms to our study as the breakdown 
of cases into AML, ALL and bilineage/biphenotypic 
leukaemia showed nearly the same statistics.  
Only one case was of biphenotypic leukaemia which 
showed both myeloid and lymphoid differentiation 
which corresponded to an international study that had 
also shown lymphoid and myeloid differentiation.22 
The limitation in our study was the lack of cytogenetic 
studies as cytogenetic evolution is one of the criteria of 
accelerated phase due to lack of the availability of this 
facility.21,22 
 
Conclusion 
 
There is usually not a single criterion for the transition 
into accelerated phase but certain variables coexist at 
the same time. In the blast phase, myeloid 
transformation is most common followed by lymphoid 
and then mixed-lineage transformation. 
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